Table 2.
Statistical performance of QSAR models from 100 times of 51-chemical-hold-out testing (mean and standard deviation) for PKCθ inhibitors.
| Paraa | RF | SVM | PLS | |||
|---|---|---|---|---|---|---|
| Training | Test | Training | Test | Training | Test | |
| Size | 157 | 51 | 157 | 51 | 157 | 51 |
| R2 | 0.95 ± 0.003 | 0.58 ± 0.09 | 0.82 ± 0.01 | 0.49 ± 0.10 | 0.64 ± 0.13 | 0.41 ± 0.13 |
| Q2 | 0.57 ± 0.03 | - | 0.59 ± 0.02 | - | 0.39 ± 0.11 | - |
| R2pred | - | 0.56 ± 0.09 | - | 0.45 ± 0.10 | - | 0.10 ± 0.84 |
| SEE | 0.24 ± 0.01 | - | 0.39 ± 0.01 | - | 0.53 ± 0.09 | - |
| SEP | - | 0.59 ± 0.06 | - | 0.63 ± 0.05 | - | 0.79 ± 0.25 |
R2, coefficient of determination; Q2, cross-validated R2: Q2 based on OOB, 10-fold cross-validation and leave-one-out for RF, SVM and PLS, respectively; R2pred, predictive correlation coefficient for the test set; SEE, standard error of estimate; SEP, standard error of prediction; -, not applicable or available.